Abstract:Recently, PEGylation has been extensively employed to increase the circulation time of liposomes and enhance their accumulation in tumor tissue via the enhanced permeability and retention (EPA) effect; however, poly(ethylene glycol) (PEG) is unfavorable for the uptake of liposomes by tumor cells because of its steric hindrance. In this study, thiolytic cleavable PEG modified liposomes were used to solve this dilemma. Before arrival at the tumor tissue, PEG presents on the surface of liposomes, which is useful for passive accumulation in tumor tissue. Upon reaching the tumor tissues, the PEG chain could be removed by a safe cleaving reagent L-cysteine (L-Cys), and thus, the steric hindrance of PEG could be overcome conveniently. To further improve the uptake of liposomes, a "functional molecule" cell-penetrating peptide TAT was attached to the distal end of a shorter PEG spacer anchored to the surface of the liposomes, which could be shielded by cleavable PEG during circulation; upon arriving at tumor tissue, PEG was removed and thus the "functional molecule" TAT was exposed, and then TAT could mediate the uptake of the liposomes with high efficiency. In this study, thiolytic cleavable PEG was synthesized via a disulfide bridge, DOPE-PEG(1600)-TAT was synthesized by sulfhydryl-maleimide reaction, and then Rh-PE labeled liposomes composed of 2% DOPEPEG(1600)-TAT and various amounts of cleavable PEG(5000) (2%, 4%, and 8%) were prepared, with particle size around 100 nm and slightly negative charge. These liposomes showed good stability in the presence of 10% serum. Their uptake by tumor cells HepG2 in vitro was assessed qualitatively and quantitatively. Liposomes modified with 2% DOPE-PEG(1600)-TAT and 8% DOPES-S-mPEG(5000) were regarded as the optimal formulation. In this preparation, nearly no uptake could be observed before addition of L-Cys, which meant undesired uptake during circulation could be avoided, while the uptake upon addition of L-Cys was 4 times as high as that in the absence of L-Cys. For the uptake in vivo, calcein loaded and Rh-PE labeled 8% cleavable PEG +2% TAT modified liposomes were injected intratumorally into H22 tumor bearing mice. Confocal laser scanning microscopy (CLSM) showed that the uptake of 8% cleavable PEG + 2% TAT modified liposomes was much higher than that of 8% noncleavable PEG + 2% TAT modified liposomes in the presence of L-Cys. Thus, tumor targeted delivery could be achieved efficiently by the liposomal drug delivery system developed here in a controlled manner.

A Synthetic Peptide Mediated Active Targeting of Cisplatin Liposomes to Tie2 Expressing Cells.

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

Harnessing Phosphato-Platinum Bonding Induced Supramolecular Assembly for Systemic Cisplatin Delivery

Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors*

A Novel Small Peptide As a Targeting Ligand for Receptor Tyrosine Kinase Tie2

PHSCNK-Modified and Doxorubicin-Loaded Liposomes As a Dual Targeting System to Integrin-Overexpressing Tumor Neovasculature and Tumor Cells.

Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide

Novel Peptide Ligand Directs Liposomes Toward Egf-R High-Expressing Cancer Cells in Vitro and in Vivo

Deepened Cellular/subcellular Interface Penetration and Enhanced Antitumor Efficacy of Cyclic Peptidic Ligand-Decorated Accelerating Active Targeted Nanomedicines

Targeted Anti-Cancer Therapy: Co-Delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-Modified Lipid Nanoparticles for Enhanced Anti-Angiogenic Efficacy

Cell-Penetrating Peptide Modified PEG-PLA Micelles for Efficient PTX Delivery

Targeted Delivery of Cargoes into A Murine Solid Tumor by A Cell-Penetrating Peptide and Cleavable Poly(Ethylene Glycol) Comodified Liposomal Delivery System Via Systemic Administration

Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.

Peptide Ligand Targeted Delivery to EGFR Expressing Cancer Cells in Vitro and in Vivo

Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer

Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features

Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation

Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications

An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery

Polyethylene glycol-polyethylenimine-tetrachloroplatinum (IV): A novel conjugate with good abilities of antitumor and gene delivery

Novel Strategy Utilizing Extracellular Cysteine-Rich Domain of Membrane Receptor for Constructing D-Peptide Mediated Targeted Drug Delivery Systems: A Case Study on Fn14